Highlights Aytu BioPharma, Inc.

Equities

AYTU

US0547548588

Delayed Nasdaq Other stock markets 10:14:10 10/05/2024 pm IST			5-day change	1st Jan Change
3.23 ^USD	+0.62%		+7.31%	+13.73%

14/02	Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024
14/02	Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M	15/02	MT
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	15/02	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M	15/11	MT
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	15/11	CI
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party	27/23/27	MT
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement	26/23/26	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M	28/23/28	MT
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	28/23/28	CI
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/23/28	CI
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority	31/23/31	CI
Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement	10/23/10	CI
Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	12/23/12	CI
Aytu BioPharma Subleases A Portion of Its Manufacturing Facility	01/23/01	CI
Aytu Biopharma, Inc. Announces Successfully Completion of Cotempla XR-ODT Bioequivalence Study	27/23/27	CI
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	22/23/22	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q2 Revenue $26.3M	22/23/22	MT
Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients	10/23/10	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $27.7M, vs. Street Est of $24.3M	15/22/15	MT
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	15/22/15	CI
Aytu Biopharma Announces Continuing Availability of Adhd Medication Adzenys Xr-Odt(R) in Response to Reported Generic Adderall(R) Xr Supply Disruptions	05/22/05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aytu BioPharma, Inc.

Equities

AYTU

US0547548588

Highlights

Filters